



## EUROPEAN GENERIC MEDICINES ASSOCIATION

### Biosimilar Medicines:


## 9<sup>th</sup> EGA International Symposium

14 - 15 April 2011

Millennium Hotel London Mayfair  
44 Grosvenor Square, London W1K 2HP, UK

Thursday | 14 April 2011

EGA International Symposium on Biosimilar Medicines

- 12:30 Registrations & Welcome Buffet Lunch sponsored by  **SANDOZ**
- Session One | Markets are Moving Up**  
Chair | **Didier Barret**, EMEA President, France CEO, Mylan and President EGA
- 14:00 Opening Address - Didier Barret**, EMEA President, France CEO, Mylan and President EGA
- 14:10 European Biosimilars - How to Enhance the Competitiveness of this EU Industry - **Greg Perry**, Director General, EGA
- 14:25 Biological/Biotechnological and Biosimilars' Market: the Global Outlook - **Alan Sheppard**, Global Head Generics, Thought Leadership, IMS Health, UK
- 14:55 Biosimilars: From here to Profitability: What was Accomplished and What is yet to be Done? - **Ronny Gal**, Specialty Pharma Analyst, Sanford Bernstein, USA
- 15:30 Coffee Break
- Session Two | International Developments: Biosimilars Go Global**  
Chair | **Greg Perry**, Director General, EGA
- 16:00 US Patient Protection and Affordable Care Act: What is the Overall Current FDA Thinking? - **Janice M. Soreth**, MD, Deputy Director, FDA Europe Office, Office of International Programs
- 16:30 The Emerging Biosimilars Landscape in Asia Pacific - **Paul Greenland**, Biosimilars Marketing Director - EMEA, Hospira, UK and Chair of the EGA Biosimilars Market Access Group
- 17:00 Global Development Programs: a Prerequisite for Worldwide Availability, Affordability and Patient Access to Biosimilars - **Ameet Mallik**, Global Head, Sandoz Biopharmaceuticals, DE
- 17:30 Panel Discussion on Global Development Programs Increasing Availability of Biosimilar Medicines and Patient Access - *Session Speakers and Peter Richardson*, Head of Biologicals, Sector Quality of Medicines, European Medicines Agency (EMA)

EUROPEAN GENERIC MEDICINES ASSOCIATION  
Rue d'Arlon 50, B-1000 Brussels, Belgium  
T: +32-(0)2-736 8411 F: +32-(0)2-736 7438  
E: [info@egagenerics.com](mailto:info@egagenerics.com) [www.egagenerics.com](http://www.egagenerics.com)  
VAT: BE 0449 332 209



## EUROPEAN GENERIC MEDICINES ASSOCIATION

- 18:00 Official Launch of EGA Biosimilars Handbook Edition 2011  
- Presentation of the handbook - **Suzette Kox**, Senior Director Scientific Affairs, EGA  
- Health Economic Benefits of Biosimilars - **Paul Cornes**, MD, Bristol Oncology Centre, Royal United Hospital Bath, Bath, UK
- 18:30 End of Day Cocktail

Friday | 15 April 2011

EGA International Symposium on Biosimilar Medicines

- 08:00 Networking Coffee
- Session Three | The Evolving EU Framework (1)**  
Chair | **Joerg Windisch**, Head Global Technical Development, Sandoz Biopharmaceuticals, AT and Chair of the EGA European Biopharmaceuticals Group
- 09:00 **Keynote Address - Professor Bruno Flamion**, Immediate Past Chair Scientific Advice Working Party (SAWP), CHMP; Professor Clinical Pharmacology, University of Namur, BE and Chair of the Belgian Committee for Reimbursement of Medicines (CTG/CRM)
- 09:30 **Perspectives of the EU Biosimilar Medicines Working Party (BMWP) - Christian Schneider**, CHMP Member, Head of Division EU Cooperation/Microbiology, Paul Ehrlich Institute, DE and Chair of the EMA Working Party on Similar Biological Medicinal Products (BMWP)
- 10:00 **EGA Perspective on Draft Guideline on Biosimilar Monoclonal Antibodies**  
**Islah Ahmed**, Global Medical Director, Hospira Inc.
- 10:30 **Questions and Answers Session**
- 11:00 Coffee Break
- Session Four | The Evolving EU and International Framework (2)**  
Chair | **Cornelia Ulm**, Senior Director Regulatory Affairs - Biologics, Mylan GmbH, CH and Vice-Chair of the EGA European Biopharmaceuticals Group
- 11:30 **EGA Perspective on Draft Guideline on Immunogenicity Assessment of Monoclonal Antibodies - Tom May**, Research R&D Fellow, Hospira Inc.
- 12:00 **Risk Management for Biologicals in the Context of the New EU Pharmacovigilance Legislation - Jan Petracek**, CEO, European Pharmed Services, CZ
- 12:30 **Global Development of Biosimilars: How can Science Inform Policymaking? - Nikhil Mehta**, Vice President, Biologics, Global Regulatory Affairs, Merck and Co., USA
- 13:00 Buffet Lunch

EUROPEAN GENERIC MEDICINES ASSOCIATION  
Rue d'Arlon 50, B-1000 Brussels, Belgium  
T: +32-(0)2-736 8411 F: +32-(0)2-736 7438  
E: [info@egagenerics.com](mailto:info@egagenerics.com) [www.egagenerics.com](http://www.egagenerics.com)  
VAT: BE 0449 332 209



## EUROPEAN GENERIC MEDICINES ASSOCIATION

Making Medicines Affordable

### Session Five | Interchangeability and Substitution

Chair | **Udo Müller**, Global Medical Director BioGenerics - Global Branded Products, TEVA Pharmaceutical Industries Ltd.

- 14:00 **The Original “Interchangeable Biosimilars”:** The Substitutability of Pre- And Post-Manufacturing Change Biologics & their Implications for Interchangeable Biosimilars - **John M. Engel, Esq.**, Managing Partner, Engel & Novitt, LLP, Washington, D.C., USA
- 14:30 **Biosimilars, Information Gap and Barriers to Substitution**  
**Arnold Vulto**, Deputy Head Hospital Pharmacy, Professor of Hospital Pharmacy and Practical Therapeutics at Erasmus University Medical Center Rotterdam, NL and Editor-in-Chief at the European Journal of Hospital Pharmacy
- 15:00 **Panel Discussion with Session Speakers, Steinar Madsen, MD, FACP (Hon)**, Medical Director, Department of Drug Information, Norwegian Medicines Agency & **Anthony Grosso**, Formulary and Medicines Management Pharmacist, University College London Hospitals NHS Foundation Trust, London, UK
- 15:30 **Closing Remarks - Suzette Kox**, Senior Director Scientific Affairs, EGA
- End of Symposium Coffee

EUROPEAN GENERIC MEDICINES ASSOCIATION  
Rue d'Arlon 50, B-1000 Brussels, Belgium  
T: +32-(0)2-736 8411 F: +32-(0)2-736 7438  
E: [info@egagenerics.com](mailto:info@egagenerics.com) [www.egagenerics.com](http://www.egagenerics.com)  
VAT: BE 0449 332 209



## EUROPEAN GENERIC MEDICINES ASSOCIATION

Making Medicines Affordable

### PLATINUM SPONSOR



### MEDIA PARTNERS



For more information [www.egagenerics.com](http://www.egagenerics.com)

EUROPEAN GENERIC MEDICINES ASSOCIATION  
Rue d'Arlon 50, B-1000 Brussels, Belgium  
T: +32-(0)2-736 8411 F: +32-(0)2-736 7438  
E: [info@egagenerics.com](mailto:info@egagenerics.com) [www.egagenerics.com](http://www.egagenerics.com)  
VAT: BE 0449 332 209